


Highlights in 2023

Progress

GENEGUT has already made significant progress over its first year towards the development of an oral RNA-based therapy for Crohn's disease. Five deliverables have been successfully submitted, including the first two scientific deliverables on "D2.1 Characterisation and validation of inside-out organoids" and "D3.1 Identification of capsule coating polymers to target payload release".



GENEGUT GA in Budapest, Hungary

Meetings

GENEGUT benefits from the strong collaboration within the consortium. In 2023, GENEGUT gathered for **2 in-person General Assembly meetings** hosted in [Cork, IE \(January\)](#) and [Budapest, HU \(September\)](#), one online GA, **monthly management board meetings** and continuous work package meetings. This enables the continuous monitoring of progress as well as risks.

Communications

With the efforts of WP6, GENEGUT has gained a large online following over its first year including strong links to patient groups via the involvement of patient association EFCCA. GENEGUT makes use of its [website](#) and [social media channels](#) to raise awareness about the project (#WhatsOnWednesdays social media series), RNA-based therapy (#GENEGUTexplains videos) and Crohn's disease (GENEGUT patient stories blogs).

[1 Year of GENEGUT](#)

[Patient stories](#)

[#GENEGUTexplains](#)

[World IBD Day](#)

